Ellen Ingalla
Genentech · 75 works · 1,315 citations · h-index 13
Top works
- Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
- Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
- Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
- GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer
- The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
- Loss of Nrdp1 Enhances ErbB2/ErbB3–Dependent Breast Tumor Cell Growth
- Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
- MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer
- Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer
- Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes
- Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
- Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha
- Negative regulation of signaling by the EGFR family
- Conjugation of Indoles to Antibodies through a Novel Self‐Immolating Linker
- Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and The novel Bcl-2 selective Inhibitor GDC-0199 Results in superior In Vitro and In Vivo Anti-tumor activity in models Of B-Cell Malignancies
- Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer
- Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927
- Abstract 3406: GDC-9545: A pure antiestrogen clinical candidate that immobilizes the estrogen receptor and profoundly alters chromatin accessibility in vivo
- Physiologically‐based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans